Herbal Drug Commercialization

Commercialisation of a herbal drug candidate requires the convergence of the scientific, quality, and regulatory workstreams described throughout this text with commercial considerations including manufacturing scale-up, supply chain security for a botanically variable raw material, market positioning relative to competing products, and, increasingly, sustainability credentials addressing the ethical and ecological sourcing of the source plant. Successful herbal drug commercialisation typically requires securing a reliable, quality-consistent supply of raw material — frequently necessitating direct contract cultivation arrangements with farmers rather than reliance on wild collection, in order to guarantee both the volume and the phytoconstituent consistency required for standardised commercial-scale manufacture — together with the analytical and regulatory infrastructure to support ongoing batch release testing and periodic regulatory renewal. The Indian herbal and Ayurvedic products sector has grown into a substantial commercial industry, led by companies such as Dabur, Himalaya, Patanjali, and Zandu, whose commercial success has been built substantially on the standardisation and quality-control discipline described in Phase 5, illustrating that rigorous science and commercial viability are complementary rather than competing objectives in modern phytopharmaceutical development.